-
Jan. 7, 2021
Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for the Treatment of Dry Age-Related Macular Degeneration (AMD) in Patients with Complement Factor H (CFH) Loss of Function Gene Variants
CAMBRIDGE, Mass. – January 7, 2021 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that GEM103, the Company’s investigational treatment for dry AMD, has been granted Fast Track designation by the United States Food and Drug Administration (FDA). Gemini is evaluating GEM103, a …
-
Nov. 13, 2020
Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Study
Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that the Phase 1 study of GEM103, the Company’s investigational treatment for dry AMD, met all its endpoints.
-
Nov. 10, 2020
Gemini Therapeutics to Participate in Upcoming Investor Conferences
Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenberg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November.
-
Oct. 15, 2020
Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration
CAMBRIDGE, Mass. and SAN FRANCISCO – October 15, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), and FS Development Corp. (Nasdaq: FSDC), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement. Upon closing of the transaction, the company will be renamed “Gemini Therapeutics, Inc.” (Combined Company) and will be led by Jason Meyenburg, Chief Executive Officer of Gemini. The Combined Company’s common stock is expected to be listed on Nasdaq.
-
Sep. 10, 2020
Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration
CAMBRIDGE, Mass. —(BUSINESS WIRE)— Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced the initiation of enrollment in its Phase 2a “ReGAtta” study.
-
Aug. 27, 2020
Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director
Ophthalmology innovator brings more than 20 years of clinical and drug development experience to the Board of Directors. CAMBRIDGE, Mass. —(BUSINESS WIRE)— Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Dr. Tuyen Ong has been appointed to serve …
-
May. 7, 2020
Gemini Therapeutics Appoints Marc E. Uknis, MD, FACS as Chief Medical Officer
CAMBRIDGE, Mass. – May 7, 2020 – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that Marc E. Uknis MD, FACS has been appointed to serve as Chief Medical Officer, effective today. Dr. Uknis brings more than 35 years of …
-
Apr. 28, 2020
Gemini Therapeutics Appoints David Lubner as Independent Director
CAMBRIDGE, Mass. – Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced that David Lubner has been appointed to serve as an independent member of its Board of Directors. “David is an accomplished finance executive, with more than 20 years of …
-
Feb. 26, 2020
Gemini Therapeutics and Singapore Eye Research Institute Enter Into Research Collaboration to Explore New Targets for Age-related Macular Degeneration
CAMBRIDGE, Mass.—(BUSINESS WIRE)—Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry Age-related Macular Degeneration (AMD) and linked ocular disorders, today announced a collaboration with the Singapore Eye Research Institute (SERI) to expand knowledge and identify new targets associated with AMD. Under the terms of the agreement, SERI and Gemini will explore …
-
Jan. 9, 2020
Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration
Study is enrolling patients with high-risk genetic variants for dry AMD, a common cause of blindness. Potential to initiate a Phase 2 study supported by the CLARITY natural history study data. Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for dry age-related macular degeneration (AMD) and linked ocular disorders, today announced it …
